thailanstatin A

Thailanstatin A is a natural product-derived small molecule that serves as a potent cytotoxic payload for antibody-drug conjugates (ADCs). Isolated from the bacterium *Burkholderia thailandensis*, it belongs to the spliceostatin class of compounds and functions as a spliceosome inhibitor. Its primary mechanism involves binding to the SF3b subunit of the U2 small nuclear ribonucleoprotein (snRNP) complex, which disrupts the recognition of the branch point sequence during pre-mRNA splicing. This inhibition leads to defective splicing, cell cycle arrest, and the induction of apoptosis in cancer cells. Shanghai Hisun Pharmaceutical Technology is developing Thailanstatin A as a specialized payload for oncological ADC applications, with the project currently in preclinical manufacturing development stages, including bench-scale and pilot-scale validation.

Other names

Thailanstatin A